UNSPSC 51422340: Dexamethasone phosphate

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H30FO8P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2BP70L44PR, chemically known as 9-fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 21-(dihydrogen phosphate) but more generally known as dexamethasone phosphate, which bears US NIH Compound Identifier 9400. European Medicines Agency schedules Dexamethasone phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01612MIG.

UNSPSC 51422340 Dexamethasone phosphate is a Commodity code that nominally covers a single corticosteroid pharmaceutical, but the recent state and local opportunities posted under this code show little alignment with the code's stated scope. The code has historically been used to classify pharmaceutical procurement, though the specific opportunities recorded show demand for naloxone and drug deactivation systems (Seminole County, Florida) and exploratory market intelligence on direct-to-manufacturer prescription programs (Texas Health and Human Services Commission). State and local health departments, county public health authorities, and state HHS agencies solicit under pharmaceutical codes when procuring emergency response medications, pharmacy benefit management support, and related drug delivery infrastructure. The issuing bodies include county health departments and state health and human services commissions, with Florida and Texas as the principal recent sources of activity.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, through competitive sealed bidding with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor information regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring how the state could establish direct contracting relationships with pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The mismatch between the code's nominal scope (dexamethasone phosphate, a specific injectable corticosteroid) and the recent opportunities (naloxone, drug deactivation systems, and prescription program infrastructure) signals that this code may be attracting broader pharmaceutical and drug-response procurement that does not align with the Commodity definition, or that state and local procurement systems are applying the code inconsistently to pharmaceutical categories.